Replies to post #4013 on Arch Therapeutics Inc (ARTH)

[Amatuer17]

Another route is what few otherbio-techs have done - example AVX_

Do a r/s - uplist to nasdaq - enter into financing agreement with financiers like LPC - this route allows company to issue shares to LPC at different price points in next 36 months depending on 10 day avg price - no additional warrants - allows company to fund operations based on needs

Downside - there is constant supply of shares and keeps price down till big news comes

Alternatively - do a r/s - uplist and carry a secondary offering - will co funds but dilution maybe at one time and thus may not be able to take advantge of increased price for funding based on good news